$POAI News

Last published 11mo ago

11mo agoPOAIPredictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementGlobeNewswirePITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native
12mo agoPOAIPredictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset StrategyGlobeNewswirePITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility
1y agoPOAIPredictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury StrategyGlobeNewswireAppoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel,
1y agoPOAIPredictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury StrategyGlobeNewswireInvestment creates the world's first Strategic Compute Reserve Strategy complements Predictive Oncology's AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025 (GLOBE NEWSWIRE) --
1y agoPOAIPredictive Oncology Announces 1-for-15 Reverse Stock SplitGlobeNewswirePITTSBURGH, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.
1y agoPOAIPredictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer PatientsGlobeNewswirePITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying and validating
1y agoPOAIPredictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of
1y agoPOAIPredictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development OpportunitiesGlobeNewswire$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in the U.S. and
1y agoLH POAIPredictive Oncology Develops Functional 3D Organoid Models Exclusively for LabcorpGlobeNewswirePITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for
1y agoPOAICourt Denies Renovaro Motion for an Expedited Trial in JulyGlobeNewswirePITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a
1y agoPOAI RENBUPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyGlobeNewswireLOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has
1y agoPOAI RENBRenovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyGlobeNewswireLOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has
1y agoPOAIAI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe AcquisitionGlobeNewswirePITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data to aggressively
1y agoPOAIPredictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"GlobeNewswireLatest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing With the global biomarker discovery market valued at $14.5 billion in 2024 and projected to
1y agoPOAIPredictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of
1y agoAVAI GEHC POAI TDOC+1Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based TechnologiesGlobeNewswirePALM BEACH, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial Intelligence (AI) is becoming more essential in the medical markets every day, it seems. AI algorithms have demonstrated
1y agoADMA AVAI POAI RXRX+1Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant GrowthGlobeNewswirePALM BEACH, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to reports from industry insiders the Global AI in Diabetic Retinopathy market is projected to continue to grow at a
1y agoPOAIPredictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned DrugsGlobeNewswireNew indications discovered by applying active machine learning and using samples from the company's vast biobank of live-cell tumors specimens Builds upon Predictive's biomarker discovery platform to select targeted
1y agoPOAI RENBRenovaro Provides Update to Definitive Agreement with Predictive OncologyGlobeNewswireLOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today
1y agoPOAIPredictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate UpdateGlobeNewswirePITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository
1y agoPOAIPredictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and OvaryGlobeNewswireCompany successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds represent true drug
1y agoPOAIPredictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal IndustriesGlobeNewswireDeal positions STREAMWAY® Systems with an established market leader to drive accelerating growth Transaction allows Predictive Oncology to be highly focused on its core AI-driven drug discovery capabilities and
1y agoPOAI RENBRenovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive OncologyGlobeNewswireCompany Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States Renovaro's
1y agoPOAI RENBPredictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro BiosciencesGlobeNewswirePredictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States Renovaro's recent
1y agoPOAIPredictive Oncology Closes Registered Direct OfferingGlobeNewswirePITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) ("Predictive Oncology" or the "Company"), a leader in AI-driven drug discovery and biologics, today closed its previously announced
1y agoONCY GRAL DGX RENB+1Investors Eye Biotech Sector as Cancer Therapy Market SurgesPR NewswireUSA News Group News Commentary – Amid the excitement surrounding Project Stargate—the $500 billion investment aimed at revolutionizing AI-driven data ...
1y agoPOAIPredictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswirePITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) ("Predictive Oncology" or the "Company"), a leader in AI-driven drug discovery and biologics, today announced that it has entered
1y agoPOAIPredictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug RepurposingGlobeNewswireCompany successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types Creates significant business development opportunities with meaningful
1y agoPOAIPredictive Oncology Partners with Switzerland-Based Tecan Group Ltd. to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D AnalysisGlobeNewswireStudy used Predictive Oncology's vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient tumor spheroids Results presented at the 2025 Society for Laboratory Automation
1y agoPOAIAIRNA Appoints Matthew Hawryluk as Chief Business OfficerBusiness WireAIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer.
1y agoPOAIPredictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling AssayGlobeNewswireInitial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan.
1y agoCTV POAI RHE SSTKKuehn Law Encourages SSTK, RHE, CTV, and POAI Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
1y agoPOAI RENBRenovaro Issues Shareholder Letter and Provides Corporate UpdateGlobeNewswireCompany to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial
1y agoPOAI RENBRenovaro to Acquire Predictive Oncology in All-Stock TransactionGlobeNewswireAcquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical
1y agoPOAI RENBPredictive Oncology Announces Agreement to be Acquired by RenovaroGlobeNewswire- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders' interest, augment
1y agoPOAIPredictive Oncology Announces Progress in Ongoing Evaluation of Strategic AlternativesGlobeNewswirePITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic alternatives, which was
1y agoPOAIPredictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic UpdateGlobeNewswirePITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of
2y agoPOAIPredictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswirePITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one
2y agoPOAIPredictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug DiscoveryGlobeNewswireStudy further validates highly reproducible drug response data. Enables AI platform to model and predict patient outcomes on historical samples Global biospecimen market valued at $4.4 billion in 2023, expected to
2y agoPOAIPredictive Oncology Inc. (POAI) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoPOAIPredictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswirePITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of
2y agoPOAIPredictive Oncology Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline DevelopmentGlobeNewswireFindings demonstrate real-world applications of Company's AI platform to support biomarker discovery, clinical trial optimization and target validation Proprietary tool accounts for patient heterogeneity and
2y agoPOAIPredictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024GlobeNewswirePITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive
2y agoPOAIPredictive Oncology Announces Exercise of Warrants for $1.26 Million Gross ProceedsGlobeNewswirePITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise
2y agoPOAIPredictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling ResultsGlobeNewswireExpands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology Biomarker discovery market estimated by third party research to be $51.5 billion in
2y agoPOAIPredictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)GlobeNewswireCompany files expansive intellectual property protection for "Membrane Protein Factory" to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at
2y agoPOAIPredictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug DiscoveryGlobeNewswirePredictive Oncology's organ-specific in vitro models are designed to better mimic the physiological environment of human tissue The 3D cell culture market is projected to grow by more than 14% annually, from $1.4
2y agoPOAIPredictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024GlobeNewswirePITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond Vennare, Chief Executive Officer, is scheduled to
2y agoPOAIPredictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswirePITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company
2y agoPOAIPredictive Oncology Inc. (POAI) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts